HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) and maintained a price target of $85 for the stock.